A Research Agenda for Malaria Eradication: Drugs

被引:87
作者
Alonso, Pedro L. [1 ]
Djimde, Abdoulaye [2 ]
Kremsner, Peter [3 ]
Magill, Alan [4 ]
Milman, Jessica [5 ]
Najera, Jose [6 ]
Plowe, Christopher V. [7 ]
Rabinovich, Regina [5 ]
Wells, Timothy [8 ]
Yeung, Shunmay [9 ]
机构
[1] Univ Barcelona, Barcelona Ctr Int Hlth Res, Hosp Clin, Barcelona, Spain
[2] Univ Bamako, Bamako, Mali
[3] Univ Tubingen Hosp, Inst Trop Med, Tubingen, Germany
[4] Walter Reed Grp, Kensington, MD USA
[5] Bill Melinda Gates Fdn, Seattle, WA USA
[6] WHO, Madrid, Spain
[7] Univ Maryland, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21201 USA
[8] Med Malaria Venture, Geneva, Switzerland
[9] London Sch Hyg & Trop Med, London WC1, England
基金
比尔及梅琳达.盖茨基金会;
关键词
ARTEMISININ RESISTANCE; ANTIMALARIAL; EFFICACY;
D O I
10.1371/journal.pmed.1000402
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Antimalarial drugs will be essential tools at all stages of malaria elimination along the path towards eradication, including the early control or "attack'' phase to drive down transmission and the later stages of maintaining interruption of transmission, preventing reintroduction of malaria, and eliminating the last residual foci of infection. Drugs will continue to be used to treat acute malaria illness and prevent complications in vulnerable groups, but better drugs are needed for elimination-specific indications such as mass treatment, curing asymptomatic infections, curing relapsing liver stages, and preventing transmission. The ideal malaria eradication drug is a coformulated drug combination suitable for mass administration that can be administered in a single encounter at infrequent intervals and that results in radical cure of all life cycle stages of all five malaria species infecting humans. Short of this optimal goal, highly desirable drugs might have limitations such as targeting only one or two parasite species, the priorities being Plasmodium falciparum and Plasmodium vivax. The malaria research agenda for eradication should include research aimed at developing such drugs and research to develop situation-specific strategies for using both current and future drugs to interrupt malaria transmission.
引用
收藏
页数:9
相关论文
共 40 条
[1]   PFMDR1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian-Thai border [J].
Alker, Alisa P. ;
Lim, Pharath ;
Sem, Rithy ;
Shah, Naman K. ;
Yi, Poravuth ;
Bouth, Denis Mey ;
Tsuyuoka, Reiko ;
Maguire, Jason D. ;
Fandeur, Thierry ;
Ariey, Frederic ;
Wongsrichanalai, Chansuda ;
Meshnick, Steven R. .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2007, 76 (04) :641-647
[2]   A Research Agenda for Malaria Eradication: Vaccines [J].
Alonso, Pedro L. ;
Ballou, Ripley ;
Brown, Graham ;
Chitnis, Chetan ;
Loucq, Christian ;
Moorthy, Vasee ;
Saul, Allan ;
Wirth, Dyann .
PLOS MEDICINE, 2011, 8 (01)
[3]   Benefits of using multiple first-line therapies against malaria [J].
Boni, Maciej F. ;
Smith, David L. ;
Laxminarayan, Ramanan .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (37) :14216-14227
[4]  
Bruce-Chwatt L. J., 1959, Bulletin of the World Health Organization, V21, P737
[5]   Early results of integrated malaria control and implications for the management of fever in under-five children at a peripheral health facility: a case study of Chongwe rural health centre in Zambia [J].
Chanda, Pascalina ;
Hamainza, Busiku ;
Mulenga, Susan ;
Chalwe, Victor ;
Msiska, Charles ;
Chizema-Kawesha, Elizabeth .
MALARIA JOURNAL, 2009, 8
[6]  
CLYDE DF, 1965, WHOMAL50665
[7]   Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America [J].
Cortese, JF ;
Caraballo, A ;
Contreras, CE ;
Plowe, CV .
JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (07) :999-1006
[8]   Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening [J].
Cox-Singh, Janet ;
Davis, Timothy M. E. ;
Lee, Kim-Sung ;
Shamsul, Sunita S. G. ;
Matusop, Asmad ;
Ratnam, Shanmuga ;
Rahman, Hasan A. ;
Conway, David J. ;
Singh, Balbir .
CLINICAL INFECTIOUS DISEASES, 2008, 46 (02) :165-171
[9]  
DOLA SK, 1974, E AFR MED J, V51, P529
[10]   Artemisinin resistance: current status and scenarios for containment [J].
Dondorp, Arjen M. ;
Yeung, Shunmay ;
White, Lisa ;
Nguon, Chea ;
Day, Nicholas P. J. ;
Socheat, Duong ;
von Seidlein, Lorenz .
NATURE REVIEWS MICROBIOLOGY, 2010, 8 (04) :272-280